KR20150115963A - 파킨슨병의 치료에 유용한 카테콜아민 유도체 - Google Patents

파킨슨병의 치료에 유용한 카테콜아민 유도체 Download PDF

Info

Publication number
KR20150115963A
KR20150115963A KR1020157026863A KR20157026863A KR20150115963A KR 20150115963 A KR20150115963 A KR 20150115963A KR 1020157026863 A KR1020157026863 A KR 1020157026863A KR 20157026863 A KR20157026863 A KR 20157026863A KR 20150115963 A KR20150115963 A KR 20150115963A
Authority
KR
South Korea
Prior art keywords
compound
formula
vacuo
compounds
benzo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020157026863A
Other languages
English (en)
Korean (ko)
Inventor
모르텐 외르겐센
베뉘 방-안데르센
아스크 퓌슬
닐스 뫼르크
제니퍼 라센
Original Assignee
하. 룬드벡 아크티에셀스카브
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39877715&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20150115963(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 하. 룬드벡 아크티에셀스카브 filed Critical 하. 룬드벡 아크티에셀스카브
Publication of KR20150115963A publication Critical patent/KR20150115963A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/08—Aza-anthracenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Portable Nailing Machines And Staplers (AREA)
KR1020157026863A 2007-08-31 2008-08-28 파킨슨병의 치료에 유용한 카테콜아민 유도체 Ceased KR20150115963A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200701250 2007-08-31
DKPA200701250 2007-08-31
PCT/DK2008/050214 WO2009026934A1 (en) 2007-08-31 2008-08-28 Catecholamine derivatives useful for the treatment of parkinson' s disease

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020097027342A Division KR101597367B1 (ko) 2007-08-31 2008-08-28 파킨슨병의 치료에 유용한 카테콜아민 유도체

Publications (1)

Publication Number Publication Date
KR20150115963A true KR20150115963A (ko) 2015-10-14

Family

ID=39877715

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020097027342A Expired - Fee Related KR101597367B1 (ko) 2007-08-31 2008-08-28 파킨슨병의 치료에 유용한 카테콜아민 유도체
KR1020157026863A Ceased KR20150115963A (ko) 2007-08-31 2008-08-28 파킨슨병의 치료에 유용한 카테콜아민 유도체
KR1020107004461A Ceased KR20100051834A (ko) 2007-08-31 2008-08-28 카테콜아민 유도체 및 이의 전구약물

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020097027342A Expired - Fee Related KR101597367B1 (ko) 2007-08-31 2008-08-28 파킨슨병의 치료에 유용한 카테콜아민 유도체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020107004461A Ceased KR20100051834A (ko) 2007-08-31 2008-08-28 카테콜아민 유도체 및 이의 전구약물

Country Status (29)

Country Link
EP (4) EP2195291A1 (enExample)
JP (4) JP2010536890A (enExample)
KR (3) KR101597367B1 (enExample)
CN (3) CN101687878A (enExample)
AR (2) AR068045A1 (enExample)
AU (2) AU2008291425B2 (enExample)
BR (2) BRPI0815894A2 (enExample)
CA (2) CA2691961C (enExample)
CL (2) CL2008002558A1 (enExample)
CO (2) CO6270232A2 (enExample)
CY (1) CY1117326T1 (enExample)
DK (1) DK2197883T3 (enExample)
EA (2) EA018011B1 (enExample)
ES (1) ES2557485T3 (enExample)
HR (1) HRP20151334T1 (enExample)
HU (1) HUE025882T2 (enExample)
IL (1) IL203080A (enExample)
MX (1) MX2010002210A (enExample)
MY (2) MY179527A (enExample)
NZ (2) NZ583551A (enExample)
PL (1) PL2197883T3 (enExample)
PT (1) PT2197883E (enExample)
RS (1) RS54470B1 (enExample)
SG (1) SG184711A1 (enExample)
SI (1) SI2197883T1 (enExample)
TW (2) TWI404702B (enExample)
UA (2) UA98804C2 (enExample)
WO (2) WO2009026934A1 (enExample)
ZA (2) ZA200909191B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220009949A (ko) * 2019-05-20 2022-01-25 하. 룬드벡 아크티에셀스카브 (6ar,10ar)-7-프로필-6,6a,7,8,9,10,10a,11-옥타하이드로-[1,3]디옥솔로[4',5':5,6]벤조[1,2-g]퀴놀린 및 (4ar,10ar)-1-프로필-1,2,3,4,4a,5,10,10a-옥타하이드로-벤조[g]퀴놀린-6,7-디올의 제조 공정
KR20220010482A (ko) * 2019-05-20 2022-01-25 하. 룬드벡 아크티에셀스카브 (2s,3s,4s,5r,6s)-3,4,5-트리하이드록시-6-(((4ar,10ar)-7-하이드록시-1-프로필-1,2,3,4,4a,5,10,10a-옥타하이드로벤조[g]퀴놀린-6-일)옥시)테트라하이드로-2h-피란-2-카복실산의 제조 공정

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI404702B (zh) * 2007-08-31 2013-08-11 Lundbeck & Co As H 兒茶酚胺衍生物和其前藥
US8067410B2 (en) 2008-06-27 2011-11-29 H. Lundbeck A/S Phenolic and catecholic amines and prodrugs thereof
WO2009156458A1 (en) * 2008-06-27 2009-12-30 H. Lundbeck A/S Novel phenolic and catecholic amines and prodrugs thereof
TW201035054A (en) * 2009-02-27 2010-10-01 Lundbeck & Co As H Methods of administering (4aR, 10aR)-1-n-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol and pharmaceutical compositions thereof
TW201036949A (en) * 2009-02-27 2010-10-16 Lundbeck & Co As H Treatment of dyskinesia related disorders
US10729710B2 (en) 2017-11-24 2020-08-04 H. Lundbeck A/S Catecholamine prodrugs for use in the treatment of Parkinson's disease
WO2020070099A1 (en) 2018-10-02 2020-04-09 H. Lundbeck A/S Administration of catecholamine prodrugs in combination with a 5-ht2b antagonist
US11104697B2 (en) * 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11130775B2 (en) * 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
EP3972970A1 (en) * 2019-05-21 2022-03-30 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
WO2020234277A1 (en) 2019-05-21 2020-11-26 H. Lundbeck A/S Catecholamine carbamate prodrugs for use in the treatment of parkinson s disease
EP3972971A1 (en) * 2019-05-21 2022-03-30 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's diseases
EP3972959A1 (en) * 2019-05-21 2022-03-30 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
CN114478298B (zh) * 2020-11-12 2024-09-27 成都西岭源药业有限公司 一种造影剂碘佛醇的纯化方法
CN116568672A (zh) * 2020-11-17 2023-08-08 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药
CN113620760A (zh) * 2021-09-07 2021-11-09 张家口思睿凯科技有限公司 一种电子盐反应液和不饱和芳香烃类化合物的还原方法
WO2025078574A1 (en) * 2023-10-12 2025-04-17 Integrative Research Laboratories Sweden Ab NOVEL ESTERS OF 1,2,3,4,4a,5,6,7,8,9,10,10a-DODECAHYDROBENZO[g]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4080456A (en) * 1971-10-26 1978-03-21 Schering Aktiengesellschaft Diacylapomorphines
CH648300A5 (en) * 1979-06-22 1985-03-15 Sandoz Ag Phenanthrene derivatives and medicaments containing them
US4543256A (en) * 1982-03-17 1985-09-24 Northeastern University (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers
WO1990012574A1 (en) * 1989-04-25 1990-11-01 Northeastern University Dopamine agonist compounds
IE903127A1 (en) * 1989-08-30 1991-03-13 Sankyo Co Indolobenzoquinoline derivatives, their preparation and¹their use as anti-arrhythmic drugs
TW357143B (en) * 1995-07-07 1999-05-01 Novartis Ag Benzo[g]quinoline derivatives
JPH11515030A (ja) * 1995-11-10 1999-12-21 ノボ ノルディスク アクティーゼルスカブ シス−ベンズ［ｅ］インドール化合物のエナンチオマー、これらの製造、及びドーパミン−Ｄ３受容体選択的医薬としての利用
CN1241998A (zh) * 1996-10-30 2000-01-19 伊莱利利公司 苯并[f]喹啉酮的合成
SE0102036D0 (sv) 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
SE0002934D0 (sv) * 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
AR030357A1 (es) * 2000-08-18 2003-08-20 Lundbeck & Co As H Derivados 4 -, 5 -, 6 - y 7-indol
US20050090518A1 (en) * 2003-10-24 2005-04-28 Nastech Pharmaceutical Company Inc. Method for treating parkinson's disease using apomorphine and apomorphine prodrugs
TWI404702B (zh) * 2007-08-31 2013-08-11 Lundbeck & Co As H 兒茶酚胺衍生物和其前藥

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220009949A (ko) * 2019-05-20 2022-01-25 하. 룬드벡 아크티에셀스카브 (6ar,10ar)-7-프로필-6,6a,7,8,9,10,10a,11-옥타하이드로-[1,3]디옥솔로[4',5':5,6]벤조[1,2-g]퀴놀린 및 (4ar,10ar)-1-프로필-1,2,3,4,4a,5,10,10a-옥타하이드로-벤조[g]퀴놀린-6,7-디올의 제조 공정
KR20220010482A (ko) * 2019-05-20 2022-01-25 하. 룬드벡 아크티에셀스카브 (2s,3s,4s,5r,6s)-3,4,5-트리하이드록시-6-(((4ar,10ar)-7-하이드록시-1-프로필-1,2,3,4,4a,5,10,10a-옥타하이드로벤조[g]퀴놀린-6-일)옥시)테트라하이드로-2h-피란-2-카복실산의 제조 공정

Also Published As

Publication number Publication date
HRP20151334T1 (hr) 2016-01-01
EA201070327A1 (ru) 2010-08-30
AR068045A1 (es) 2009-10-28
CY1117326T1 (el) 2017-04-26
UA97989C2 (uk) 2012-04-10
TW200911752A (en) 2009-03-16
PL2197883T3 (pl) 2016-03-31
ZA201001422B (en) 2011-06-29
MY148948A (en) 2013-06-14
JP5802792B2 (ja) 2015-11-04
CN107253956A (zh) 2017-10-17
NZ583551A (en) 2012-07-27
MY179527A (en) 2020-11-10
AU2008291425B2 (en) 2012-12-06
EA200971107A1 (ru) 2010-06-30
CO6270232A2 (es) 2011-04-20
EP3009437A1 (en) 2016-04-20
CA2697688A1 (en) 2009-03-05
BRPI0815894A2 (pt) 2015-02-24
EP2197883A1 (en) 2010-06-23
WO2009026935A1 (en) 2009-03-05
CL2008002558A1 (es) 2009-08-07
TWI404702B (zh) 2013-08-11
CO6260082A2 (es) 2011-03-22
NZ582379A (en) 2011-08-26
EA018011B1 (ru) 2013-04-30
AU2008291426A1 (en) 2009-03-05
CL2008002564A1 (es) 2009-07-17
CN101687878A (zh) 2010-03-31
CN101842354A (zh) 2010-09-22
UA98804C2 (ru) 2012-06-25
ES2557485T3 (es) 2016-01-26
EP2662358A1 (en) 2013-11-13
AU2008291426B2 (en) 2013-01-31
AR068044A1 (es) 2009-10-28
KR20100051834A (ko) 2010-05-18
WO2009026934A1 (en) 2009-03-05
SI2197883T1 (sl) 2016-01-29
EA018413B1 (ru) 2013-07-30
DK2197883T3 (en) 2016-01-11
JP2014111635A (ja) 2014-06-19
KR101597367B1 (ko) 2016-02-24
CA2691961C (en) 2013-12-17
JP2010536889A (ja) 2010-12-02
JP2014148528A (ja) 2014-08-21
PT2197883E (pt) 2016-02-02
EP2197883B1 (en) 2015-11-18
SG184711A1 (en) 2012-10-30
IL203080A (en) 2014-11-30
AU2008291425A1 (en) 2009-03-05
KR20100046111A (ko) 2010-05-06
TW200914426A (en) 2009-04-01
JP2010536890A (ja) 2010-12-02
ZA200909191B (en) 2011-03-30
RS54470B1 (sr) 2016-06-30
MX2010002210A (es) 2010-03-17
CA2691961A1 (en) 2009-03-05
BRPI0813456A2 (pt) 2014-12-23
HUE025882T2 (en) 2016-04-28
EP2195291A1 (en) 2010-06-16
JP5548125B2 (ja) 2014-07-16

Similar Documents

Publication Publication Date Title
KR101597367B1 (ko) 파킨슨병의 치료에 유용한 카테콜아민 유도체
US8129530B2 (en) Catecholamine derivatives and prodrugs thereof
JP2011525893A (ja) 新規のフェノールアミン類およびカテコールアミン類ならびにそのプロドラッグ
HK1237782A (en) Catecholamine derivatives useful for the treatment of parkinson’s disease and method of preparing the same
HK1237782A1 (en) Catecholamine derivatives useful for the treatment of parkinson’s disease and method of preparing the same
HK1148737A (en) Catecholamine derivatives and prodrugs thereof
HK1142072A (en) Catecholamine derivatives useful for the treatment of parkinson's disease
HK1191333A (en) Catecholamine derivatives and prodrugs thereof
AU2013203089A1 (en) Catecholamine derivatives and prodrugs thereof
US20120196889A1 (en) Catecholamine derivatives and prodrugs thereof

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20150925

Application number text: 1020097027342

Filing date: 20091229

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20151203

Patent event code: PE09021S01D

PE0601 Decision on rejection of patent

Patent event date: 20160215

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20151203

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I